Search Within

Michael Morris

Formats
  1. Meeting Abstract (273)
  2. Journal Article (266)
  3. Review (19)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
Groups
  1. Department of Medicine (580)
  2. Genitourinary Oncology Service (580)
  3. Solid Tumor Oncology Division (580)
  4. Radiology, Department of (163)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (140)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (21)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (238)
  2. Journal of Nuclear Medicine (43)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (248)
  2. American Association for Cancer Research (43)
  3. Society of Nuclear Medicine (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (39)
  6. Elsevier Inc. (27)

More Publishers

Results (580)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
    Journal Article

    Mitchell, A. P.; Mishra Meza, A.; Panageas, K. S.; Lipitz-Snyderman, A.; Farooki, A.; Morris, M. J.
    Prostate Cancer and Prostatic Diseases (2023)

    Fulltext@MSK | Save
  • Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer
    Meeting Abstract

    Nagar, H.; Ballman, K. V.; Tagawa, S. T.; Tan, A.; Faltas, B. M.; Sheybani, A.; Baghaie, S.; Schwartz, L. H.; Kozono, D. E.; Bogart, J. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Automated analysis of FDG-PET/CT imaging to monitor heterogeneous disease response in metastatic castration-resistant prostate cancer
    Meeting Abstract

    Barnett, E.; Woo, S.; Perk, T. G.; Munian-Govindan, R.; Lokre, O.; Gajar, R. N.; Erazo, T.; Carbone, E.; Morris, M. J.; Vargas, H. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)
    Meeting Abstract

    Aggarwal, R. R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer
    Meeting Abstract

    Zaidi, S.; Chan, J. M.; Love, J.; Zhao, J.; Setty, M.; Lawrence, K.; Gopalan, A.; Goodrich, D.; Morris, M. J.; Chen, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Barriers to guideline-concordant use of bone modifying agents for prostate cancer
    Meeting Abstract

    Mitchell, A. P.; Persaud, S.; Chimonas, S.; Salner, A. L.; Palyca, P.; Farooki, A.; Ostroff, J. S.; Morris, M. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Linch, M. D.; Crabb, S. J.; Beer, T. M.; Heath, E. I.; Gordon, M. S.; De Bono, J. S.; Pashova, H. I.; Tudor, I. C.; Greenstein, A. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Changes in planned disease management after piflufolastat F(18) PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study
    Meeting Abstract

    Pouliot, F.; Gorin, M. A.; Rowe, S. P.; Saperstein, L.; Denes, B. S.; DiPippo, V. A.; Stambler, N.; Morris, M. J.; Siegel, B. A.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Management of patients with advanced prostate cancer. Part I: Intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
    Journal Article

    Gillessen, S.; Bossi, A.; Davis, I. D.; de Bono, J.; Fizazi, K.; James, N. D.; Mottet, N.; Shore, N.; Small, E.; Smith, M.; more...
    European Urology (2023)

    Fulltext@MSK | Save